{"nctId":"NCT00289744","briefTitle":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","startDateStruct":{"date":"2004-02-16","type":"ACTUAL"},"conditions":["Hepatitis B","Hepatitis A"],"count":178,"armGroups":[{"label":"Twinrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: TWINRIX™ ADULT"]},{"label":"Engerix-B Additional Dose (Adult)","type":"EXPERIMENTAL","interventionNames":["Biological: Engerix TM"]},{"label":"Engerix-B Additional Dose (Pediatric)","type":"EXPERIMENTAL","interventionNames":["Biological: Engerix TM"]}],"interventions":[{"name":"TWINRIX™ ADULT","otherNames":[]},{"name":"Engerix TM","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects participating in this study should have participated in the primary study with combined hepatitis A/ hepatitis B vaccine.\n* Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood sampling visit of each year.","healthyVolunteers":true,"sex":"ALL","minimumAge":"7 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"692.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"753.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"544.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"479.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"601.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1431.9","spread":null},{"groupId":"OG001","value":"565.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Immune Response to the Additional Dose of Engerix™-B","description":"Immune response was defined as:\n\n* anti-hepatitis B surface antigen (anti-HBs) antibody concentration equal or above to 10 milli-international units per milliliter (mIU/mL) at 1 month post-challenge dose in subjects seronegative at the pre-challenge time-points\n* at least a 4-fold increase in anti-HBs antibody concentrations at 1 month post-challenge dose in subjects seropositive at the pre-challenge time-points.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs) Assessed by the Investigator as Causally Related to Primary Vaccination, Study Procedures or Lack of Vaccine Efficacy","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Solicited Local and General Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Unsolicited Adverse Events","description":"Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Pain","Fatigue","Redness","Gastrointestinal symptoms","Headache"]}}}